Business
Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol "RKV"
Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"\n \n \n \n Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol \"RKV\"\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n The company will focus on the development of novel DNA-damage repair (DDR) inhibitors for the treatment of cancer\n \n \n \n /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN\n \n THE UNITED STATES\n \n . ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./\n \n \n \n VANCOUVER, BC\n \n ,\n \n April 1, 2021\n \n /CNW/ -\n \n Rakovina Therapeutics Inc. (the \"\n \n \n Company\n \n \n \")\n \n (TSX-V: RKV) is pleased to announce the commencement of trading on the TSX Venture Exchange under the symbol \"RKV\" following the completion of its previously announced qualifying transaction (the \"\n \n Qualifying Transaction\n \n \"), the detail of which is  described in the Company's press release dated\n \n March 25, 2021\n \n and prior announcements available at\n \n www.sedar.com\n \n .\n \n \n \n \n \n \n \n \n \n In connection with the closing of the qualifying transaction and commencement of trading the Company:\n \n \n \n Acquired certain rights to three novel series of DNA-damage response inhibitors\n \n \n \n \n Raised gross proceeds of\n \n $4,565,900\n \n in an oversubscribed private placement\n \n \n \n \n Established a research collaboration with the\n \n University of British Columbia\n \n to undertake lead-optimization and pre-clinical development activities\n \n \n \n \n Appointed\n \n Jeffrey Bacha\n \n (Executive Chairman),\n \n Mads Daugaard\n \n (President & CSO),\n \n John Langlands\n \n (COO) and\n \n David Hyman\n \n (CFO & Corporate Secretary) as Executive Officers\n \n \n \n \n Appointed\n \n Jeffrey Bacha\n \n ,\n \n Dennis Brown\n \n ,\n \n Al Delucrezia\n \n and\n \n Michael Liggett\n \n to the Board of Directors\n \n \n \n \"The capitalization of Rakovina Therapeutics and commencement of trading on the TSX Venture Exchange is a major milestone...